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Abstract
Introduction
Patients with distributive shock who require high dose vasopressors have a high mortality.
Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite
catecholamine and vasopressin therapy. The appropriate dose of parenteral angiotensin II for
shock is unknown.

Methods
In total, 20 patients with distributive shock and a cardiovascular Sequential Organ Failure
Assessment score of 4 were randomized to either ATII infusion (N = 10) or placebo (N = 10)
plus standard of care. ATII was started at a dose of 20 ng/kg/min, and titrated for a goal of
maintaining a mean arterial pressure (MAP) of 65 mmHg. The infusion (either ATII or
placebo) was continued for 6 hours then titrated off. The primary endpoint was the effect of
ATII on the standing dose of norepinephrine required to maintain a MAP of 65 mmHg.

Results
ATII resulted in marked reduction in norepinephrine dosing in all patients. The mean hour 1
norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min versus 7.4 ± 12.4
mcg/min for the ATII cohort (P = 0.06). The most common adverse event attributable to
ATII was hypertension, which occurred in 20% of patients receiving ATII. 30-day mortality
for the ATII cohort and the placebo cohort was similar (50% versus 60%, P = 1.00).

Conclusion
Angiotensin II is an effective rescue vasopressor agent in patients with distributive shock
requiring multiple vasopressors. The initial dose range of ATII that appears to be appropriate
for patients with distributive shock is 2 to 10 ng/kg/min.

Trial registration
Clinicaltrials.gov NCT01393782. Registered 12 July 2011.

Introduction
Critically ill patients with shock requiring vasopressors are at a high risk of death.
Distributive shock is the most common form of shock, and is often caused by sepsis [1].
When shock is treated with vasopressors, two main classes of vasopressors are in the
intensivists’ armamentarium: catecholamines and vasopressin type peptides [1]. Currently, no
specific type of vasopressor (e.g. norepinephrine, vasopressin, dopamine) compared to
another vasopressor has been shown to improve outcome [2]. All vasopressors have
limitations and potential side effects. Patients treated with catecholamines for shock often
develop tachyphylaxis thereby limiting the utility of these agents, and high doses of
catecholamines can cause direct cardiotoxicity [3]. The toxic potential of catecholamines has
been recently demonstrated in a randomized clinical trial of septic shock patients treated

norepinephrine [4]. In this study, beta-blockade with esmolol was shown to improve survival
in these patients by decreasing the heart rate. Thus, vasopressors that are not inotropes or
chronotropes may be useful in patients with shock. One such vasopressor is vasopressin,
which is most commonly used as an adjuvant with catecholamines. Vasopressin has been
shown to improve outcomes in patients with less severe septic shock, but has toxicity (i.e.
cardiac and mesenteric ischemia) at high doses and interacts with hydrocortisone [5]. In the
subset of critically ill patients in whom mean arterial pressure cannot be maintained with
vasopressors, distributive shock is uniformly fatal. The addition of a ‘rescue’ vasopressor in
this setting could be useful.
Angiotensin II is a naturally occurring hormone with endocrine, autocrine, paracrine, and
intracrine hormonal effects. It is a potent direct vasoconstrictor, constricting both arteries and
veins and increasing blood pressure [6].It has a half-life in circulation of approximately 30
seconds, but while in tissue, its half-life may be as long as 15-30 minutes. Importantly, ATII
increases secretion of ADH and ACTH, and may potentiate sympathetic effects by direct
action on postganglionic sympathetic fibers. It also acts on the adrenal cortex, causing it to
release aldosterone [6,7]. We hypothesized that ATII might serve a role as a useful
vasopressor in the treatment of shock, but the appropriate dose of intravenous ATII to
increase blood pressure is unknown. The dose of intravenous ATII previously described has
varied across studies, but has ranged from 0.4 ng/kg/min to as high as 40 ng/kg/min. The
highest doses were reported in the cases of profound hypotension due to ACEi overdose
[8,9]. We set out to determine the appropriate dose of ATII in the treatment of high output
shock.

Methods
The study was conducted at the George Washington University Hospital Intensive Care Unit,
Washington DC, USA. The trial was registered on clinicatrials.gov (NCT01393782) and the
study protocol was approved by Food and Drug Administration (IND# BB-IND-11592). The
protocol was approved by the George Washington University Institutional Review Board.
Written informed consent was obtained from each participating patient, or appropriate
surrogate prior to enrollment. The investigators performed all experimental procedures and
the study coordinators recorded the data.

Study patients
Patients were eligible for randomization if they were older than 21 years of age and were
deemed to have high output shock, which was defined as a cardiovascular Sequential Organ
Function Assessment (SOFA) score of 4 as well as a cardiac index of > 2.4 liters/min/BSA
1.73 m2 [10]. Patients were also required to have an indwelling arterial line and urinary
catheter as part of standard care and expected to be present for at least 12 hours during the
study intervention. In addition, the treating team had to deem the subject adequately volume
resuscitated and clinically assessed not to be volume responsive (i.e. a fluid bolus would fail
to increase cardiac index by 15%). Standard of care at our institution is to resuscitate with 2030 cc/kg of crystalloid as initial resuscitation. Exclusion criteria included patients with acute
coronary syndrome, a known history of vasospasm or asthma, any patients currently
experiencing bronchospasm or patients with active bleeding with an anticipated need for
transfusion of > 4 units of packed red blood cells, hemoglobin <7 g/dL or any other condition
that would contraindicate drawing serial blood samples.

Treatment assignments
Upon enrollment in the study, patients were randomly assigned following simple
randomization procedures (computerized random numbers) to receive either angiotensin II
acetate infusion (Clinalfa, Bachem AG, Hauptstrasse 144, 4416 Bubendorf, Switzerland) or a
placebo infusion (hereafter referred to as the Study Drug and placebo, respectively).
Randomization was accomplished by the Investigational Drug Services (IDS) at George
Washington University Hospital. For the duration of the entire study, only the IDS was aware
of each patient’s treatment assignment. Unblinding was done after all 20 patients were
enrolled. All other clinical personnel, including the investigators, clinical support staff, the
patients and their families were unaware of the treatment assignment for the duration of the
study.

Drug infusion
Enrolled patients were randomized to receive the Study Drug infusion in normal saline
calculated to run at a drip rate corresponding to an initial concentration of 20 ng/kg/min, plus
the standard-of-care treatment for high output shock. The Study Drug was prepared in an
opaque cellophane bag, the contents of which were unknown to the investigators, nurses or
anyone else taking direct care of the patient. The Study Drug was administered for a total of 6
hours, with dose (and corresponding drip rate) adjustments made hourly. Study Drug dose
adjustments were determined per a pre-specified protocol, based on the concomitant
requirements of standard-of-care therapy (in all cases, norepinephrine infusion plus
vasopressin, epinephrine and/or phenylephrine infusions) needed to maintain a mean arterial
pressure (MAP) at or above 65 mm Hg, which is the standard practice at our institution. The
Study Drug titration protocol was designed to elucidate the dose of ATII that was required (in
conjunction with a norepinephrine dose between 5-10 mcg/min) to achieve the
aforementioned standard MAP goal of 65 mm Hg. The dose titration protocol is shown on
Figure 1. The maximum allowable dose for the ATII titration was 40 ng/kg/min, and the
minimum was 5 ng/kg/min. At the end of 6 hours, the Study Drug infusion was titrated off by
being halved every 10 minutes until the Study Drug infusion dose was below 5 ng/kg/min,
after which it was discontinued.
Figure 1 Study Drug titration protocol.

End points
The primary endpoint was the effect of the ATII infusion on the standing dose of
norepinephrine which was required to maintain a MAP of 65 mmHg. The secondary
endpoints included the effect of the ATII infusion on urine output, serum lactate, cardiac
output, and 30 day mortality.

Statistical analysis
This was a safety and dose finding feasibility study. We analyzed a small cohort of patients,
consistent with similar studies of this nature. We estimated that a population of 20 patients,
ten patients in each arm, would generate a basis for determining if there was sufficient signal
for ATII to affect the dose of norepinephrine at the doses outlined herein. An independent

data and safety monitor (DSM) was assigned and reviewed all adverse events. The DSM had
the power to be unblinded and halt the study at any time during the conduct of the study.
We assessed the distribution of demographic and clinical variables. Difference between
proportions of patients with certain variables was assessed with the chi-square, Fisher exact
test, student t, and Mann-Whitney test as appropriate. The primary endpoint of the effect of
the Study Drug infusion on the standing dose of norepinephrine was calculated using a
general estimating equation analysis and is presented as the mean dose of norepinephrine
(mcg/min) and Study Drug infusion (in ng/kg/min) at hourly intervals.
Generalized estimating equation was used to model the response to the Study Drug over time,
with standard-of-care vasopressor hourly readings beginning at 1 hour prior to, through 8
hours after the initiation of the Study Drug, using the SAS Genmod procedure (version 9.3,
Cary, NC). Correlation structure was defined as auto-regressive to account for the likely
higher correlation between time points that were closer together. In this model, the main
effect of drug examines the mean response to each drug averaged across times. The main
effect of time examines the mean response at each time point averaged across drugs, and the
drug multiplied by time interaction examines whether the change over time differs between
drugs.
All values are reported as mean ± standard deviation unless otherwise specified. All other
statistical analysis was completed using SPSS 18, Chicago, IL, USA.

Results
The flow of patients into the study is reported in Figure 2. Twenty patients underwent
randomization and all 20 patients were enrolled in and completed the study (Figure 1).
Baseline characteristics of the two groups are shown in Table 1. The mean age for all study
subjects was 62.9 ± 15.8 years. Of the patients, 75% were male, 45% were Caucasian and
40% were African American. Baseline SOFA and APACHE II scores were 15.9 ± 3.0 and
30.6 ± 8.9, respectively. 19 of 20 patients were receiving concomitant vasopressin at a dose
of 0.02-0.08 u/min. Vasopressin doses were not adjusted during the study period.
Figure 2 Patient Flow Diagram.
Table 1 Baseline demographic and clinical data
Age
Male (n)
Race (n)
Caucasian
Black
Other
Severity of Illness
Baseline SOFA
APACHE
Past Medical History
IHD
CHF

FullCohort SD
62.85
15.81
15

ATII
68.40
6

9
8
3

6
3
1

15.90
30.60
2
2

2.97
8.86

14.9
27.2
1
2

SD
17.46

2.81
9.67

Placebo SD
57.30
12.44
9

P valueϮ
0.12
0.30

3
5
2

0.37
0.65
1.00

16.90
34.00
1
0

2.92
6.83

0.14
0.09
1.00
0.47

COPD
DM
CKD
HD
Liver disease
Cancer
IS
Steroids
Hypertension
CVA
AKI
Labs
WBC
Hgb
Creatinine
pH
Lactate
Baseline vasopressor dosesY
Norepinephrine
Vasopressin

2
7
7
1
9
6
6
3
9
5
17

2
4
3
0
5
1
1
1
4
4
9

17.38
9.45
2.33
7.33
5.83

19.0
9.16
1.89
7.34
4.59

16.0
2.14
1.03
0.11
3.11

15.72
9.73
2.76
7.32
7.06

12.3
2.45
1.34
0.12
5.16

0.61
0.59
0.12
0.63
0.21

19.80
0.03

11.67
0.02

30.30
0.05

20.37
0.02

0.18
0.10

25.05
0.04

17.03
0.02

0
3
4
1
4
5
5
2
5
1
8

0.47
1.00
1.00
1.00
1.00
0.14
0.14
1.00
1.00
0.30
1.00

Ϯ

P values for continuous variables calculated using Student's T test. P values for discrete
variables calculated using Fisher exact test.
Y
One patient in the placebo group received phenylephrine infusion prior to initiation of ATII
versus no patients in the ATII group. One patient in the placebo group received epinephrine
versus no patients in the ATII group.
IHD = ischemic heart disease. CHF = congestive heart failure. COPD = chronic obstructive
pulmonary disease. DM = diabetes mellitus. CKD = chronic kidney disease. HD =
hemodialysis. IS = immunocompromised state. CVA = cerebrovascular accident. AKI =
acute kidney injury.
ATII resulted in a reduction in norepinephrine dosing in all patients (Figure 3). The mean
Hour 1 norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min v. 7.4 ± 12.4
mcg/min for the ATII cohort (p = 0.06). Hour 2 norepinephrine dosing for the placebo cohort
was 28.6 ± 30.2 mcg/min v. 7.3 ± 11.9 mcg/min in the ATII cohort (p =0.06). Throughout the
study period, the mean ATII dose was reduced from 20 ng/kg/min at Hour Zero to 5
ng/kg/min at Hour 6 before being titrated off by Hour 7 (one hour post-infusion). Despite this
down-titration of ATII, norepinephrine doses remained substantially lower in the ATII cohort
than the placebo cohort, though the effect approached statistical significance only at Hours 1
and 2. Upon cessation of the ATII infusion, mean norepinephrine rebounded concomitantly.
Figure 3 Changes in Norepinephrine Dose with Concurrent Angiotensin II.
Using a general estimating equation model with time defined as a continuous variable, in
order to obtain a global test of interaction effect, the main effect of treatment (Study Drug vs.
placebo) was not significant (p = 0.13), nor was the effect of time (p = 0.30), nor was the
treatment multiplied by time interaction (p = .76). When time was defined as a class variable
with Hour -1 defined as the reference group, in order to examine specific time points, the
drug effect (p = .14) and time effect (p = .18 at time 0, p = .51 at time 1) both remained non-

significant. The product of drug multiplied by time interaction showed a trend level of
significance at 1-hr and 2-hr (p = 0.06).
Adverse events most commonly experienced by all patients were metabolic disorders with
alkalosis occurring in four patients in the ATII group and zero in the placebo group (p =
0.09). The most common adverse event thought to be attributable to ATII was hypertension,
which occurred in 20% of patients receiving ATII (p = 0.58). In both of these patients, the
Study Drug infusion was stopped, per protocol, in order to achieve MAP goals. Table 2 lists
adverse events.
Table 2 Adverse events
Organ System
Metabolic disorders
Acidosis
Alkalosis
Blood or lymphatic disorders
Respiratory disorders
Worsening respiratory failure
Wheezing
Cardiac disorders
Hypertension◊
Hypotension
Atrial Fibrillation
Renal disordersY
Decreased urine output
Worsening AKI
Other disordersϮ
Worsening MOSF

Total
16

7
6

12

7

8

ATII
11
2
4
3
3
1
1
7
2
2
2
6
3
0
5
2

Placebo
5
3
0
4
3
3
0
5
0
1
0
1
1
2
3
3

P value
1.00
0.09

0.58
1.00
0.58
1.00
0.47
0.58
0.47
1.00

◊

ATII infusion was discontinued in two patients due to hypertension.
Seventeen of 20 patients exhibited pre-existing AKI, including 8 patients receiving placebo
and 9 patients receiving ATII. Of the three patients that did not have pre-existing AKI, one
patient developed AKI and received ATII.
Ϯ
Includes worsening multiple organ system failure, fever, lower extremity edema, and thigh
hematoma.
AKI = acute kidney injury. MOSF = multiple organ system failure. P values calculated using
Fisher Exact test.
Y

Urine output, cardiac output, central venous pressure, and mean arterial pressure are shown in
Table 3. The 30 day mortality for the two groups were similar for the ATII cohort and the
placebo cohort (50% v. 60%, p = 1.00).

Table 3 Secondary outcomes
Urine Output
ATII
Placebo
Cardiac Output
ATII
Placebo
CVP
ATII
Placebo
MAP
ATII
Placebo
Lactate
ATII
Placebo

Hr -2

Hr -1

Hr 0

41.7(51.7)
29.5(69.8)

28.6(32.4) 45.9(96.5) 31.1(58.0) 33.7(67.1) 42.6(59.8) 35.9(50.0) 34.4(57.2) 36.1(38.3) 27.2(33.3) 23.8(27.3)
12.4(23.2) 23.5(41.8) 17.5(25.7) 17.0(32.0) 16.3(24.6) 17.0(34.7) 16.8(30.4) 14.8(26.3) 18.0(27.3) 23.0(34.4)

7.0(2.7)
6.3(1.2)

6.0(3.1)
6.9(2.5)

6.6(2.6)
6.5(1.7)

6.3(2.5)
6.9(1.8)

6.2(2.5)
6.4(1.7)

5.9(2.7)
6.8(3.0)

6.5(2.4)
7.3(2.2)

6.1(2.6)
6.8(1.5)

6.7(3.3)
7.3(1.8)

6.3(2.9)
6.9(2.5)

7.5(3.1)
7.0(2.3)

12.7(5.5)
16.0 (3.0)

12.9(7.0)
9.7(2.1)

14.1(8.9)
12.6(7.8)

14.8(7.3)
15.7(9.3)

14.6(7.4)
17.3(9.0)

14.8(8.8)
15.7(7.3)

11.7(3.9)
16.4(8.6)

12.1(4.8)
16.3(6.7)

10.0(2.9)
14.2(6.5)

12.6(4.8)
14.4(7.1)

11.8(3.8)
13.2(5.6)

71.2(13.6)
71.2(9.2)

72.3(11.2) 68.8(7.0) 74.8(8.4)
71.8(6.5) 73.0(12.6) 72.8(9.5)

69.8(8.6)
67.8(6.6)

73.1(12.5) 75.3(14.2) 68.9(8.1)
70.1(6.4) 71.3(7.8) 73.0(4.7)

4.6(3.1)
7.1(5.2)

Hr 1

Hr 2

Hr 3

Hr 4

Hr 5

Hr 6

Hr 7

Hr 8

73.0(10.5) 72.3(11.9) 73.6(11.5)
75.9(9.4) 74.0(10.6) 74.5(13.2)
5.2(4.1)
5.7(3.9)

Legend: Urine Output (cc), Cardiac Output (liters/min), CVP = central venous pressure; all
variables-mean (s.d.), denotes p < 0.05.

Discussion
We report the findings of the first prospective randomized placebo-controlled trial of
angiotensin II in the treatment of high output shock. Our efforts were intended as a proof-ofconcept and dose finding study, as well as an attempt to generate hypotheses in advance of
larger future studies. To this end, we have shown that ATII can be an effective pressor agent
at a dose range of 1-40 ng/kg/min. More specifically, we believe that a starting dose of 2-10
ng/kg/min may be an appropriate starting dose in the treatment of high output shock when
used in conjunction with standard-of-care vasopressors.
Angiotensin II has been used previously in for the treatment of hypotension in a handful of
cases. Newby et al describe the successful treatment of a patient with an ACE inhibitor
overdose and profound shock using an ATII infusion [11]. Multiple case reports have shown
potential utility for ATII in the treatment of septic shock with catecholamine infusions [1216].
While all patients in the present study had a response to the ATII infusion, we observed
significant heterogeneity. Of the ten patients who received ATII, two had a modest response,
while two were exquisitely sensitive to ATII, which was an unexpected finding. In the two
highly sensitive patients, the norepinephrine infusion was titrated off per protocol, and the
ATII dose was at its lowest allowable dose of 5 ng/kg/min and the patients remained
hypertensive with MAP of > 90 mm Hg despite norepinephrine titrated off. Since
hypertension is not part of our standard of care, the investigators halted the infusion, and the
ATII was weaned off. In both cases the need for norepinephrine was rapidly reestablished.
Pre-clinical studies demonstrate that animals that become septic after pre-treatment with
enalapril are resistant to norepinephrine as a vasopressor [17]. Based on these findings, we
hypothesized that the two patients who were very sensitive to ATII may have been receiving
an angiotensin converting enzyme inhibitor prior to developing septic shock, thus explaining
the exquisite sensitivity of to ATII infusion. However, a detailed chart review revealed
incomplete information, and we were unable to document pre-morbid angiotensin converting

enzyme inhibitor exposure. Therefore, the ATII sensitivity that we observed could be due to
other mechanisms that have not been elucidated.
We observed that ATII may have synergy with other vasopressors (i.e. catecholamines and
vasopressin), but may also have another important indication in critically ill patients.
Previous work in pre-clinical studies suggests that septic animals suffer acute kidney injury in
part due to intra-glomerular hypotension induced by efferent arteriole vasodilation. In these
models, intravenous infusion with ATII restored creatinine clearance and urine output [18].
While the present study was underpowered to elucidate any effect on urine output, we expect
further large scale studies will clarify ATII’s effect on kidney function in high output shock.
In addition, ATII is a potent vasopressor without inotropic or chronotropic properties [19].
Recent randomized controlled trials in patients with septic shock treated with norepinephrine
suggest that less chronotropy may be desirable and may lead to a survival benefit [4]. Based
on these findings, for patients who require norepinephrine and are tachycardic, ATII may be
particularly useful. We hypothesize that for patients with severe hypotension, lower doses of
multiple vasopressors with differing mechanisms of action may be more efficacious and less
toxic than high doses of one type of vasopressors (i.e. catecholamines).
The study had multiple strengths. First, the study was a randomized double-blind controlled
trial with an appropriate placebo control arm. Secondly, it was of pragmatic design, as it was
the intent of the investigators to enroll patients receiving standard-of-care treatment for high
output shock. As such, all patients had received a priori appropriate monitoring and
therapeutic interventions (including central venous lines, bladder catheters, arterial lines, and
cardiac output monitoring devices). There was no additional need for any specialized
equipment of procedures prior to enrollment in the study. Thirdly, all enrolled patients had a
documented need for high dose vasopressor therapy despite volume therapy, as evidenced by
the cardiac index entry criteria. This, we believe, is in keeping with the current practice of
addressing volume responsiveness in a hypotensive patient prior to initiation of vasopressor
therapy. Finally, as part of our study protocol, we employed the use of a data safety monitor,
who had the ability to unblind data and evaluate for adverse events as well as halt the study,
neither of which occurred.
The study had several limitations. First, the study had a modest sample size. As such, we
were unable to make conclusions regarding the effect of ATII on urine output due to the high
incidence of oliguria and renal replacement therapy in both the ATII group and the placebo
group. Moreover, this study was not powered adequately to discern a difference in mortality
between the ATII and placebo groups. Second, there were some imbalances between our
placebo arm and our drug arm, the former of which were younger, but sicker (according to
both SOFA and APACHE II scores). It is possible that differences in these two populations
influenced the effectiveness of ATII. Finally, inclusion criteria for enrollment in the study
were such that the resulting study population was critically ill, with an expected mortality in
excess of 50%. Indeed, our requirement of cardiovascular SOFA score of 4 (indicating a
norepinephrine dose of 0.1mcg/kg/min) would, on average, equate to a minimum
norepinephrine dose of 9.3mcg/min, which based on our Study Drug titration protocol
(Figure 1), would leave little room for titration. In order to allow for the possibility of a
meaningful signal upon initiation of ATII, we preferentially considered patients with a
substantially higher starting dose of norepinephrine (20-30 mcg/min, as evidenced in Figure
3). Moreover, we preferentially considered patients with an upward-trending norepinephrine
requirement, signifying refractoriness to therapy. Based on these facts, our results may not be

generalizable to a less sick population. However, we foresee a use for ATII in a significant
critically ill population, for whom multiple vasopressors are required.

Conclusions
In conclusion, the initiation of an ATII infusion in patients receiving norepinephrine for
septic shock resulted in a marked decrease in norepinephrine doses. ATII may be effective as
a novel pressor agent in the treatment of high output shock. Initial dosing ranges are most
likely between 2-10 ng/kg/min. In our pilot study, the drug appears to be well-tolerated.
Further randomized placebo-controlled trials to more fully elucidate ATII’s role as a
vasopressor in the treatment of shock are warranted.

Key messages
• Angiotensin II improved blood pressure in patients with high-output shock and multiple
vasopressors. Angiotensin II may have a role as a rescue vasopressor.
• The response to angiotensin II in a modest sized study were highly variable
• The precise role of angiotensin II in the treatment of hypotension and shock needs further
study
• Angiotensin II was well-tolerated in this pilot study
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